v3.25.1

Statement of Financial Position, Unclassified - Real Estate Operations - USD ($)	Dec. 31, 2024	Dec. 31, 2023
CURRENT ASSETS:
Cash	$ 1,542,442	$ 274,380
Accounts receivable	2,211	3,735
Prepaid expenses	90,789	147,262
Total current assets	1,635,442	425,377
OTHER ASSETS:
Operating lease - right of use asset	0	98,280
Security deposit	7,680	32,058
Total other assets	7,680	130,338
TOTAL ASSETS	1,643,122	555,715
CURRENT LIABILITIES:
Accounts payable	547,090	993,090
Accounts payable - related party	194,762	172,670
Current portion of long-term operating lease	0	106,342
Convertible debentures payable	0	240,000
Current portion of note payable	138,164	0
Accrued interest	65,628	100,686
Accrued liabilities - employee bonus	1,096,178	1,148,770
Total current liabilities	2,041,822	2,761,558
LONG TERM LIABILITIES:
Long-term operating lease, net of current portion	116,197	0
Total long-term liabilities	116,197	0
TOTAL LIABILITIES	2,158,019	2,761,558
STOCKHOLDERS' (DEFICIT):
Common stock, $0.001 par value, 25,000,000 and 25,000,000 shares authorized as of December 31, 2024 and December 31, 2023; 3,621,335 and 2,382,356 issued and outstanding at December 31, 2024, and December 31, 2023, respectively	3,621	2,383
Additional paid-in capital	136,448,032	121,373,488
Accumulated deficit	(136,966,550)	(123,581,714)
Total stockholders' (deficit)	(514,897)	(2,205,843)
TOTAL LIABILITIES AND STOCKHOLDERS' (DEFICIT)	$ 1,643,122	$ 555,715

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

Zivo Bioscience, Inc. 10-K